Last reviewed · How we verify
NCT07031843
Exploration of a Novel Prognostic Prediction Model for Liver Cirrhosis
trial in Cirrhosis in 300 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | Juan Kang |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 February 2023 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Conditions studied
- Cirrhosis — all drugs for Cirrhosis →
Sponsor
Juan Kang
Who can join
Adults 18 to 75, any sex, with Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The liver, a key organ for metabolism and synthesis, is involved in protein, fat, and carbohydrate metabolism, as well as energy production. Hepatic injury and functional decline can lead to metabolic abnormalities in these three major nutrients, as well as in vitamins and trace elements. Malnutrition, one of the most common complications in cirrhosis patients, has a broader impact than traditional complications like hepatic encephalopathy, esophageal variceal bleeding, refractory ascites, and spontaneous bacterial peritonitis. It is closely related to patient prognosis. Therefore, malnutrition should be considered as important as ascites and hepatic encephalopathy in diagnosis and treatment, and nutritional metabolism should be incorporated into prognostic prediction models or scoring systems for cirrhosis patients. Currently, the nutrition assessment of cirrhosis patients mostly uses relatively subjective methods such as scales and scores. There is no specific gold-standard diagnostic criterion for malnutrition in cirrhosis patients. Also, existing prognostic models for cirrhosis patients do not adequately consider the impact of nutritional factors on disease prognosis. Metabolomics technology can detect changes in the types and levels of nutritional metabolites in cirrhosis patients and analyze the differences in nutritional metabolites under various nutritional statuses and their relationship with the prognosis of cirrhosis patients. This helps objectively reveal the predictive value of nutrition metabolism for the prognosis of cirrhosis patients. However, metabolomics has been rarely used in nutrition assessment studies of cirrhosis patients and merits further research. This study will employ a prospective cohort study design to analyze the baseline nutritional status of patients with liver cirrhosis, investigate the impact of nutritional factors on long-term prognosis, and develop a prognostic prediction model for liver cirrhosis that incorporates nutritional parameters.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07031843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cirrhosis
Currently open trials in the same condition.
- NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
- NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
- NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
- NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
- NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting
Other Juan Kang trials
Trials by the same sponsor.
- NCT06328517 — The Influence of Nutritional Factors on the Prognosis of Liver Cirrhosis Patients and the Exploration of Predictive Mode · recruiting
- NCT05835102 — Influence of Nutritional Indices on the Prognosis of Patients With SARS-CoV-2 Infection · recruiting
- NCT05635279 — Effect of Nutritional Indices on the Prognosis of HCC Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07031843 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Juan Kang
- Last refreshed: 22 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07031843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing